Ginkgo Bioworks CEO Jason Kelly discusses how AI and automation can revolutionize scientific research, particularly in biotechnology. He argues that while previous tech revolutions had little impact, AI can fundamentally change how science is conducted by automating experimental work and enhancing data analysis. Kelly shares Ginkgo's partnership with OpenAI, where AI models outperformed state-of-the-art biochemistry benchmarks by 40% in cell-free protein synthesis. He envisions a future where AI-driven robotic labs accelerate scientific discovery, improve data sharing, and drastically reduce research costs. Kelly also touches on the potential for biotech to expand beyond therapeutics into consumer products, such as personalized health monitoring and lifestyle enhancements, and the importance of the US maintaining its competitive edge in science amid China's rise.
Sign in to continue reading, translating and more.
Continue
